V8 Peptides — Engineered Performance
Research Library
BPC-157 and TB-500: Reading Preclinical Parameters
BPC-157Reconstitution & Handling

BPC-157 and TB-500: Reading Preclinical Parameters

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What do published preclinical studies of BPC-157 and TB-500 report, and how does that connect to reconstitution? The primary BPC-157 papers cited here are rat studies in which the peptide was given intraperitoneally once daily at three amounts per kilogram of body weight (10 µg, 10 ng and 10 pg) after tendon surgery, plus tendon-fibroblast cell studies in culture. The thymosin β4 papers concern the full 43-residue protein in rat wound models and cell migration assays, not the seven-residue fragment sold as TB-500. For bench work, the practical question is how to turn a vial into a stock whose concentration can be compared with the ranges in such papers. That needs only two formulas: concentration = mass ÷ diluent volume, and amount per animal = concentration × volume given. V8 lists BPC-157 (10 mg), TB-500 (10 mg) and a co-lyophilized Wolverine Stack (10 mg of each). For laboratory research use only.

Protocol-style searches for these two peptides tend to blend two separate things: how a lyophilized vial is dissolved, and what published animal and cell studies actually did. This article keeps them apart. It explains how to read the parameters reported in the primary literature, how to express a stock in comparable units, and how the choice between a combined vial and two single vials affects the arithmetic. It does not recommend any amount or schedule. It relates to the broader pieces on TB-500, BPC-157 and BPC-157 vs TB-500. All content concerns laboratory research; the materials are for laboratory research use only and not for human consumption.

What the primary papers report

Reading parameters accurately matters because secondary summaries often drop the species, route or form of the peptide. The table lists what each cited paper's abstract states, and nothing more.

PaperSystemPeptideRoute and schedule as reportedAmounts as reported
Staresinic et al., 2003Rat, transected Achilles tendon; cultured tendocytesBPC-157 in saline, no carrierIntraperitoneal, once daily, first 30 min after surgery, last 24 h before analysis10 µg, 10 ng or 10 pg per kg body weight
Krivic et al., 2006Rat, Achilles tendon detached from boneBPC-157, alone or with a corticosteroidIntraperitoneal, once daily over the study window10 µg, 10 ng or 10 pg per kg body weight
Chang et al., 2011Rat tendon explants and tendon fibroblasts in cultureBPC-157Added to culture mediumConcentration-dependent effects reported across a range in the paper
Chang et al., 2014Cultured tendon fibroblastsBPC-157Added to culture mediumRange reported in the paper
Malinda et al., 1999Rat full-thickness wound; keratinocyte migration chamberThymosin β4 (full protein)Topical or intraperitoneal in rats; added to the chamber assayAs little as 10 pg in the migration assay; amounts in the animal work are in the paper
Bock-Marquette et al., 2004Mouse cardiac models and cultured cardiomyocytesThymosin β4 (full protein)As described in the paperAs described in the paper

Two caveats follow. First, "10 µg per kg" and "10 pg per kg" are amounts per unit of body weight for a rat in a specific surgical model. They are not concentrations and not a basis for any other species or purpose. Second, none of these papers used the TB-500 heptapeptide; the thymosin β4 work used the full protein, so a bench scientist citing it must say so. The relationship between the two is explained in TB-500 vs thymosin beta-4.

Turning a vial into a comparable stock

A paper that reports an amount per kilogram, or a concentration in culture medium, can be compared with a stock only through arithmetic. These are the relationships, written as formulas because the numbers depend on the vial and the experiment.

  1. Stock concentration = vial mass ÷ diluent volume added.
  2. Amount in a sample volume = stock concentration × sample volume.
  3. Working concentration after dilution = stock concentration × (stock volume ÷ final volume).
  4. Per-kilogram amount in an animal protocol = amount in the delivered volume ÷ animal body weight. Animal work is outside the scope of this article, but the formula shows why a published per-kilogram figure cannot be turned into a bench concentration without the delivered volume and the animal weight.
  5. Molar concentration = mass concentration ÷ molar mass. This is the conversion needed to compare BPC-157 (a 15-residue peptide) with the TB-500 heptapeptide or with full-length thymosin β4 on a like-for-like molar basis.

Mass-for-mass, the heptapeptide contains far more molecules than the 43-residue protein, which is one more reason not to equate results between them. The reconstitution calculator does the volume step for a specific vial, and its guide and volume calculations explain the inputs.

Combined vial or two vials

The Wolverine Stack holds BPC-157 10 mg and TB-500 10 mg in a single co-lyophilized vial, 20 mg in total, according to the product page. Single-compound vials are also listed: BPC-157 at 10 mg and TB-500 at 10 mg. The two formats give different arithmetic and different experimental freedom.

QuestionCo-lyophilized vialTwo single vials
Mass ratioFixed at 1:1 by massAny ratio, chosen per experiment
Mole ratioFixed; about 1.6 TB-500 molecules per BPC-157 molecule, from molar massesChosen
Number of pipetting stepsOne reconstitutionTwo reconstitutions plus mixing
Attributing an effect to one peptideRequires separate single-peptide arms anywayBuilt in
Concentration of each componentEach equals its mass ÷ diluent volume; both move togetherIndependent
Typical useQuestions about the combination at a fixed ratioRatio comparisons and attribution

The mole ratio in that table follows from molar masses of roughly 1,419 Da for BPC-157, which the Staresinic paper states, and about 889 Da for the TB-500 heptapeptide: equal masses contain about 1.6 times more TB-500 molecules than BPC-157 molecules. The working formula is the safest guide: moles = mass ÷ molar mass, computed for each component. The comparison of blend and separate vials in general is in blend versus separate vials, and the earlier discussion of the two together is in BPC-157 and TB-500 combination research and BPC-157 + TB-500 blend reconstitution.

Handling steps that apply to both

  • Equilibrate. Let the sealed vial reach room temperature before opening.
  • Diluent. Bacteriostatic water for a vial that will be entered repeatedly; sterile water for single-use frozen aliquots. Put the same diluent in the vehicle control.
  • Add slowly, down the wall of the vial, and swirl. Neither peptide needs vigorous mixing.
  • Aliquot once into low-binding tubes; peptide adsorption to labware is documented by Goebel-Stengel and colleagues (2011).
  • Keep cold and dark. The product pages state 2–8 °C, −20 °C for long-term, protected from heat, moisture and light.
  • Record lot, date, volumes, stock concentration and freeze–thaw count.

BPC-157 contains no cysteine, methionine or tryptophan, and TB-500 contains none either, so oxidation routes reviewed by Li and colleagues (1995) are limited; the main stresses on both are microbial growth, repeated freeze–thaw and surface loss, in line with the reviews by Manning and colleagues (2010). The general procedure is in how to reconstitute a lyophilized peptide, and shelf-life expectations in how long reconstituted peptides last; room-temperature behavior for BPC-157 is covered in BPC-157 room-temperature stability. Certificates, where published, are in the COA library.

Worked example of the formulas, with symbols

Suppose a vial of mass M is dissolved in diluent volume V. The stock concentration is C = M ÷ V. A working solution is made by taking volume v of stock and bringing it to final volume F, so the working concentration is C × v ÷ F, and the dilution factor is F ÷ v. If a paper reports a culture concentration in molar units, convert the stock first: molar stock = C ÷ molar mass, then apply the dilution factor. Keep units explicit at every step, converting micrograms and milligrams before dividing, and write each intermediate value in the record. Errors in peptide work most often come from a unit slip between mg and µg or between mL and µL, and from forgetting that a dilution changes the diluent composition as well, so the vehicle control must be diluted by the same factor. A second person checking the calculation, or the calculator output filed with the record, catches most of them.

Citing these papers responsibly

A short checklist keeps citations accurate when they are used to design an experiment.

  • State the species, model and route exactly as the paper does.
  • State whether the paper used BPC-157, full-length thymosin β4 or the TB-500 fragment.
  • Do not convert a per-kilogram amount into a culture concentration; justify the in vitro range from in vitro papers.
  • Note that much of the BPC-157 animal literature comes from one group, and that independent replication, though it exists in the cell work cited here, is limited elsewhere.
  • Include vehicle, scrambled-peptide and single-peptide controls,, as set out for migration assays in the TB-500 research overview.

Nothing in this article is a recommendation for use in people or animals. The products are supplied for laboratory research use only. See the shop for other materials.

Frequently asked questions

What did the published BPC-157 tendon studies use?

Rats with a transected or detached Achilles tendon, BPC-157 in saline given intraperitoneally once daily at 10 µg, 10 ng or 10 pg per kg body weight, as reported by Staresinic and colleagues (2003) and Krivic and colleagues (2006).

Were those amounts concentrations?

No. They are amounts per kilogram of animal body weight in a surgical model and cannot be turned into culture concentrations.

Did the thymosin β4 papers use TB-500?

No. They used the full 43-residue protein. TB-500 as listed on the product page is the seven-residue fragment Ac-LKKTETQ.

How is a stock concentration calculated?

Vial mass divided by diluent volume. A working concentration is the stock concentration times the stock volume divided by the final volume.

Does equal mass mean equal numbers of molecules?

No. BPC-157 is about 1,419 Da and the TB-500 heptapeptide about 889 Da, so equal masses hold more TB-500 molecules. Use moles = mass divided by molar mass.

What does the Wolverine Stack contain?

BPC-157 10 mg and TB-500 10 mg in one co-lyophilized vial, 20 mg in total, per the product page.

When are two single vials preferable?

When the experiment needs a ratio other than 1:1, or when an effect has to be attributed to one peptide.

Which diluent should be used?

Bacteriostatic water for a vial entered repeatedly, sterile water for single-use frozen aliquots, with the same diluent in the vehicle control.

How are the sealed vials stored?

The product pages state 2–8 °C, with −20 °C for the long term, protected from heat, moisture and light.

Are these products for use in people or animals?

No. They are supplied for laboratory research use only and are not for human or animal consumption.

Related reading: BPC-157 Complete Research Guide: Evidence and Handling, BPC-157 and GHK-Cu Combination: Study Design Guide, BPC-157 in Gastrointestinal Research Models.

References

  1. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4
  2. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. doi:10.1002/jor.20096
  3. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
  4. Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066
  5. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
  6. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
  7. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
  8. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.